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This international consensus statement is the collaborative effort
of three medical societies representing electrophysiology in North
America, Europe and Asian-Paciﬁc area: the Heart Rhythm Society
(HRS), the European Heart Rhythm Association (EHRA) and the Asia
Paciﬁc Heart Rhythm Society. The objective of the consensus
document is to provide clinical guidance for diagnosis, risk stratiﬁ-
cation and management of patients affected by inherited primary
arrhythmia syndromes. It summarizes the opinion of the interna-
tional writing group members based on their own experience and
on a general review of the literature with respect to the clinical data
on patients affected by channelopathies.
This document does not address the indications of genetic
testing in patients affected by inherited arrhythmias and their
family members. Diagnostic, prognostic, and therapeutic implica-
tions of the results of genetic testing also are not included in this
document because this topic has been covered by a recent
publication [1] coauthored by some of the contributors of this
consensus document, and it remains the reference text on this
topic. Guidance for the evaluation of patients with idiopathic
ventricular ﬁbrillation, sudden arrhythmic death syndrome and
sudden unexplained death in infancy, which includes genetic
testing, are provided as these topics were not covered in the
previous consensus statement.
Developing guidance for genetic diseases requires adaptation of
the methodology adopted to prepare guidelines for clinical prac-
tice. Documents produced by other medical societies have
acknowledged the need to deﬁne the criteria used to rank the
strength of recommendation for genetic diseases [2].
The most obvious difference encountered for inherited diseases
is that randomized and/or blinded studies do not exist in this ﬁeld.
Therefore most of the available data derive from registries that
have followed patients and recorded outcome information. As a
consequence, all consensus recommendations are level of evi-
dence (LOE) C (i.e., based on experts’ opinions).
The consensus recommendations in this document use the
commonly used Class I, IIa, IIb and III classiﬁcation and the
corresponding language: “is recommended” for Class I consensus
recommendation; “can be useful” for a Class IIa consensus recom-
mendation; “may be considered” to signify a Class IIb consensus
recommendation; and “should not” or “is not recommended” for a
Class III consensus recommendation (failure to provide any addi-
tional beneﬁt and may be harmful).Deﬁnitions of special terms used in the document
In the consensus document, the following terms will be deﬁned as: Syncope: In the context of inherited arrhythmogenic disorders,
the occurrence of “syncope” is an important indicator of
arrhythmic risk. Although there is no deﬁnition to differentiate
a syncopal episode caused by ventricular arrhythmias from an
otherwise unexplained syncope, in the context of this docu-
ment, the term “syncope” implies the exclusion of events that
are likely due to vasovagal events such as those occurring
during abrupt postural changes, exposure to heat and dehydra-
tion, emotional reactions to events such as blood drawing, etc.
We refer to the guidelines of ESC and AHA/ACCF for the
differential diagnoses of syncope [3,4]. Symptomatic individuals: The term “symptomatic” refers to
individuals who have experienced ventricular arrhythmias
(usually ventricular tachycardia or resuscitated ventricularﬁbrillation), or syncopal episodes (see deﬁnition above). The
presence of symptoms is, in some of the channelopathies, an
independent predictor of cardiac arrest at follow-up. Arrhythmic events: The term refers to the occurrence of
symptomatic or asymptomatic sustained or nonsustained
spontaneous ventricular tachycardia, or unexplained syncope/
resuscitated cardiac arrest. Concealed mutation-positive patients: This term is used to
refer to individuals without clinical symptoms or phenotype of
a channelopathy who carry the genetic defect present in
clinically affected members of the family.
Methodological aspects and instructions for the consultation of the
document
When considering the guidance from this document, it is
important to remember that there are no absolutes governing
many clinical situations. The ﬁnal judgment regarding care of a
particular patient must be made by the health care provider and
the patient in light of all relevant circumstances. Recommenda-
tions are based on consensus of the writing group following the
Heart Rhythm Society’s established consensus process. It is recog-
nized that consensus does not mean unanimous agreement among
all writing group members. We identiﬁed the aspects of patients'
care for which a true consensus could be found. Surveys of the
entire writing group were used. The authors received an agree-
ment that was equal to or greater than 84% on all recommenda-
tions; most recommendations received agreement of 94% or
higher.
This statement is directed to all health care professionals who
are involved in the management of (1) individuals who survived a
cardiac arrest at a young age (usually deﬁned as o40 years) in the
absence of a clinical diagnosis of cardiac disease, despite extensive
clinical assessment; (2) family members of individuals who died
suddenly at young age with a negative autopsy; (3) in patients and
family members in whom the diagnosis of a channelopathy is
clinically possible, likely, or established; and (4) young patients
with unexplained syncope.
All members of this document writing group provided disclo-
sure statements of all relationships that might present real or
perceived conﬂicts of interest. Disclosures for all members of the
writing group are published in Appendix A.2. Long QT Syndrome (LQTS)Expert Consensus Recommendations on LQTS Diagnosis
1. LQTS is diagnosed:
(a) In the presence of an LQTS risk score ≥3.5 in the
absence of a secondary cause for QT prolongation and/
or
(b) In the presence of an unequivocally pathogenic
mutation in one of the LQTS genes or
(c) In the presence of a QT interval corrected for heart rate
using Bazett's formula (QTc) ≥500 ms in repeated 12-
lead electrocardiogram (ECG) and in the absence of a
secondary cause for QT prolongation.
2. LQTS can be diagnosed in the presence of a QTc between 480–
499 ms in repeated 12-lead ECGs in a patient with
unexplained syncope in the absence of a secondary cause for
QT prolongation and in the absence of a pathogenic mutation.
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Interventions
Class I
1. The following lifestyle changes are recommended in all
patients with a diagnosis of LQTS:
(a) Avoidance of QT-prolonging drugs (www.qtdrugs.org)
(b) Identiﬁcation and correction of electrolyte
abnormalities that may occur during diarrhea,
vomiting, metabolic conditions or imbalanced diets for
weight loss.
2. Beta-blockers are recommended for patients with a diagnosis
of LQTS who are:
(a) Asymptomatic with QTc ≥470 ms and/or
(b) Symptomatic for syncope or documented ventricular
tachycardia/ventricular ﬁbrillation (VT/VF).
3. Left cardiac sympathetic denervation (LCSD) is recommended
for high-risk patients with a diagnosis of LQTS inwhom:
(a) Implantable cardioverter deﬁbrillator (ICD) therapy is
contraindicated or refused and/or
(b) Beta-blockers are either not effective in preventing
syncope/arrhythmias, not tolerated, not accepted or
contraindicated.
4. ICD implantation is recommended for patients with a diagnosis
of LQTS who are survivors of a cardiac arrest.
5. All LQTS patients who wish to engage in competitive sports
should be referred to a clinical expert for evaluation of risk.Class IIa
6. Beta-blockers can be useful in patients with a diagnosis of
LQTS who are asymptomatic with QTc ≤470 ms.
7. ICD implantation can be useful in patients with a diagnosis of
LQTS who experience recurrent syncopal events while on
beta-blocker therapy.
8. LCSD can be useful in patients with a diagnosis of LQTS who
experience breakthrough events while on therapy with beta-
blockers/ICD.
9. Sodium channelblockers can be useful, as add-on therapy, for
LQT3 patients with a QTc 4500 ms who shorten their QTc by
440 ms following an acute oral drug test with one of these
compounds.Class III
10. Except under special circumstances, ICD implantation is not
indicated in asymptomatic LQTS patients who have not been
tried on beta-blocker therapy.Epidemiology
Patients affected by the long QT syndrome (LQTS) have been
identiﬁed all over the world and in all ethnic groups. A possible
exception is represented by a paucity of cases identiﬁed among black
Africans and among African-Americans. Among Caucasians, the pre-
valence of LQTS has been established by a prospective ECG study,
complemented by molecular screening, performed on over 44,000
infants at age 15–25 days [5]. LQTS disease-causing mutations were
identiﬁed in 43% and 29% of the infants with a QTc exceeding 470 and
460 milliseconds (ms), respectively. These ﬁndings demonstrate a
prevalence of about 1:2000 apparently healthy live births (95% CI,
1:1583 to 1:4350). This prevalence reﬂects only infants with anabnormally long QTc and does not take into account the signiﬁcant
number of "concealed mutation-positive patients."
Genetic variants
Since 1995, when the ﬁrst three genes responsible for LQTS
were identiﬁed [6–8], molecular genetic studies have revealed a
total of 13 genetic forms of congenital LQTS caused by mutations
in genes encoding potassium-channel proteins, sodium-channel
proteins, calcium channel-related factors, and membrane adaptor
proteins. Patients with LQT1, LQT2, and LQT3 genotypes with
mutations involving KCNQ1, KCNH2, and SCN5A make up over
92% of patients with genetically conﬁrmed LQTS. Up to 15%–20% of
patients with LQTS remain genetically elusive [1]. Mutations in
auxiliary β-subunits to KCNQ1 (KCNE1, LQT5) and KCNH2 (KCNE2,
LQT6) are infrequent, but they result in clinical phenotypes similar
to patients with mutations in their associated α-subunits of KCNQ1
and KCNH2. A recessive form of LQTS, the Jervell and Lange-
Nielsen syndrome, involves the same (homozygous) or different
(compound heterozygous) KCNQ1 mutations from both parents, is
more virulent and is associated with deafness. Mutations in KCNJ2
(Kir2.1, LQT7) result in the neurologic musculoskeletal Andersen-
Tawil syndrome with associated QT prolongation. The remaining
LQTS genotypes (LQT4 and LQT8-13) have each been identiﬁed in
just a few families or in single individuals.
Common variants in the LQTS genes (single nucleotide poly-
morphisms [SNPs]), and in some cases unrelated genes, are
thought to contribute to the variable penetrance of LQTS within
affected family members having the same gene mutation [9].
Clinical manifestations
The clinical manifestations of LQTS fall under two main
categories: the arrhythmic events and the electrocardiographic
(ECG) aspects.
The arrhythmic events are due to runs of torsades de pointes
VT, which, according to its duration, produces syncope, cardiac
arrest, and—when it deteriorates into VF—sudden death. Among
untreated patients, the natural history is represented by the
occurrence of a number of syncopal episodes, eventually leading
to sudden death. Sudden death as a ﬁrst manifestation represents
the main rationale for the treatment of asymptomatic patients.
Atrial arrhythmias, speciﬁcally atrial ﬁbrillation, are more frequent
in LQTS patients compared to controls [10,11].
The conditions associated with arrhythmic events are, to a large
extent, gene-speciﬁc [12], with most arrhythmic events occurring
during physical or emotional stress in LQT1, at rest or in associa-
tion with sudden noises in LQT2 patients, and at rest or during
sleep in LQT3 patients.
The ECG alterations are important and numerous. While the
prolongation of the QT interval is the hallmark of LQTS, it is not
always present. Indeed, between 10% (LQT3) and 37% (LQT1) of
genotype-positive patients have a QT interval within normal limits
at rest [13]. Ventricular repolarization is not only prolonged but often
presents bizarre morphologic alterations, some of which tend to be
gene-speciﬁc [14]. Macroscopic T-wave alternans [15] is perhaps the
most distinctive ECG pattern of LQTS, and is a marker of high cardiac
electrical instability. Notches on the T-wave are rather typical for LQT2
and their presence is associated with a higher risk for arrhythmic
events [16]. Long sinus pauses are not infrequent among LQT3 patients.
Diagnosis
The diagnosis of LQTS is mainly based on measurement of the QT
interval corrected for heart rate (QTc) using Bazett's formula. When
using a prolonged QTc to diagnose LQTS, one must exclude secondary
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conditions, electrolyte imbalance, and unbalanced diets. A scoring
system has been established, which takes into account the age of the
patient, medical and family history, symptoms, and QTc and provides a
probability of the diagnosis of LQTS [17,18].
Approximately 20%–25% of patients with LQTS conﬁrmed by
the presence of an LQTS gene mutation may have a normal range
QTc [13,19]. The use of provocative tests for QT measurement
during change from a supine to standing position [20], in the
recovery phase of exercise testing [21,22], or during infusion of
epinephrine [23,24] has been proposed to unmask LQTS patients
with normal QTc at resting ECG. These tests may be considered in
uncertain cases. However, the clinical use of this test requires
more extensive validation.
Risk stratiﬁcation
Individuals at the extremes of the curve, those at very high or
at very low risk, are easy to identify. For the larger group, in the
gray area, risk stratiﬁcation is difﬁcult and can be fraught with
errors in either direction. There are genetic and clinical clues that
facilitate risk assessment.
Speciﬁc genetic variants, such as the Jervell and Lange-Nielsen
syndrome [25] and the extremely rare Timothy syndrome (LQT8) [26]
are highly malignant, manifest with major arrhythmic events very
early, and respond poorly to therapies. Within the most common
genetic groups, speciﬁc locations, types of mutations, and degree of
mutation dysfunction are associated with different risks. Mutations in
the cytoplasmic loops of LQT1 [27,28], LQT1mutations with dominant-
negative ion current effects [29], and mutations in the pore region of
LQT2 [29,30] are associated with higher risk, and the same is true even
for some speciﬁc mutations with an apparently mild electrophysiolo-
gical effect [31]. By contrast, mutations in the C-terminal region tend
to be associated with a mild phenotype [32].
Clinically, there are several patterns and groups associated with
differential risk. High risk is present whenever QTc 4500 ms [13,33]
and becomes extremely high whenever QTc 4600 ms. Patients with a
diagnosis of LQTS who are identiﬁed by genetic testing as having two
unequivocally pathogenic variants and a QTc 4500 ms (including
homozygous mutations as seen in patients with Jervell and Lange-
Nielsen syndrome) are also at high risk, in particular when they are
symptomatic. The presence of overt T-wave alternans, especially when
evident despite proper therapy, is a direct sign of electrical instability
and calls for preventive measures. Patients with syncope or cardiac
arrest before age 7 have a higher probability of recurrence of
arrhythmic events while on beta-blockers [34]. Patients who have
syncope or cardiac arrest in the ﬁrst year of life are at high risk for
lethal events and may not be fully protected by the traditional
therapies [35,36]. Patients who suffer arrhythmic events despite being
on full medical therapy are at higher risk.
By contrast, it also is possible to identify patients at lower risk.
Concealed mutation-positive patients are at low, but not zero, risk
for spontaneous arrhythmic events. The risk for an arrhythmic
event in this group has been estimated around 10% between birth
and age 40 in the absence of therapy [13]. A major risk factor for
patients with asymptomatic genetically diagnosed LQTS comes
from drugs that block the IKr current and by conditions that lower
their plasma potassium level. Among genotyped patients, LQT1
males, who are asymptomatic at a young age [37], are at low risk
of becoming symptomatic later on in life, while females, and
especially LQT2 females, remain at risk even after age 40.
Management
The aggressiveness to manage patients with LQTS is related in
part to the risk for life-threatening arrhythmic events, as highlightedin Section 2.5. The AHA/ACC/ESC Guidelines for LQTS Therapy,
published in 2006, are still relevant in 2012 [2]. Life-style modiﬁca-
tions such as avoidance of strenuous exercise, especially swimming,
without supervision in LQT1 patients, reduction in exposure to abrupt
loud noises (alarm clock, phone ringing, etc) in LQT2 patients, and
avoidance of drugs that prolong QT interval in all LQTS patients,
should be routine. Participation of LQTS patients in competitive sports
is still a matter of debate among the experts. Recently available
retrospective data suggest that participation in competitive sports of
some patients with LQTS may be safe [38]. Based on these data [38],
which still need conﬁrmation, low-risk patients, with genetically
conﬁrmed LQTS but with borderline QTc prolongation, no history of
cardiac symptoms, and no family history of multiple sudden cardiac
deaths (SCD), may be allowed to participate in competitive sports in
special cases after full clinical evaluation, utilization of appropriate
LQTS therapy and when competitive activity is performed where
automated external deﬁbrillators are available and personnel trained
in basic life support [38]. This applies especially to patients genotyped
as non-LQT1. In all patients with a high perceived risk (see Section 2.5)
and in patients with exercise-induced symptoms, competitive sport
should be avoided. Speciﬁc therapies available for patients with LQTS
and indications for their use are described below.
Beta-blockers
Beta-blockers are clinically indicated in LQTS, including those
with a genetic diagnosis and normal QTc, unless there is a
contraindication such as active asthma [34,35]. Presently, there is
no substantial evidence to favor cardioselective or noncardiose-
lective beta-blockers; however, the former is preferred in those
patients who suffer from asthma. Long-acting beta-blockers such
as nadolol or sustained-release propranolol should be preferred as
these medications can be given once or twice a day with avoidance
of wide ﬂuctuations in blood levels. Recent data also suggest that,
particularly in symptomatic patients, these drugs may perform
better than, for example, metoprolol [39]. While studies are not
available to deﬁne the most effective dosage, full dosing for age
and weight, if tolerated, is recommended. Abrupt discontinuation
of beta-blockers should be avoided as this may increase the risk of
exacerbation.
Implantable cardioverter-Deﬁbrillator (ICD) (Fig. 1)
ICD therapy is indicated in LQTS patients who are resuscitated
from cardiac arrest [40]. ICD is often favored in patients with LQTS-
related syncope who also receive beta-blockers [41]. Prophylactic
ICD therapy should be considered in very-high-risk patients such as
symptomatic patients with two or more gene mutations, including
those with the Jervell and Lange-Nielsen variant with congenital
deafness [25]. ICD therapy has life-time implications. Complications
are not infrequent, especially in the younger age group, and risk/
beneﬁt considerations should be carefully considered before initiat-
ing this invasive therapy [42,43]. Accordingly, LQT1 patients who
experience a cardiac arrest while not receiving beta-blockers may
only be treated with beta-blockers or with LCSD (see below) in
settings when the implant of an ICD is likely to be associated with
high risk, such as in infants and pediatric patients [44,45]. LQTS-
related sudden death in one family member is not an indication for
ICD in surviving affected family members unless they have an
individual proﬁle of high risk for arrhythmic events [46].
Considering the potential complications associated with the
implantation of an ICD in young individuals, we recommend
caution when using a device in asymptomatic patients. We suggest
that ICD therapy not be used as ﬁrst-line therapy in an asympto-
matic LQTS patient; beta-blockers remain the ﬁrst-line therapy
in LQTS patients. However, an ICD may be considered in those
patients who are deemed to be at very high risk, especially those
Fig. 1. Consensus recommendations for ICDs in patients diagnosed with long QT syndrome.
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an ICD implanted should be made only after a careful considera-
tion of (1) risk of sudden death; (2) the short- and long-term risks
of ICD implantation; and (3) values and preferences of the patient.
The physician must discuss the risks and beneﬁts of ICD therapy
with the patient, and patient’s values and preferences are impor-
tant in this decision.
Whenever ICD therapy is chosen, thoughtful programming (in
particular to prevent inappropriate shocks) is pertinent and usually
requires a VF-only zone, with a cutoff rate greater than 220–240 bpm.Left Cardiac Sympathetic Denervation (LCSD)
This procedure is often effective in reducing the probability for
arrhythmic events in high-risk patients, including those who are
intolerant of or refractory to beta-blockers alone [47]. The proce-
dure can be done surgically through a left supraclavicular incision
[48–50] or as a minimally invasive procedure in experienced
centers [51]. This procedure is frequently used in very-high-risk
infants and children in whom ICD therapy may be relatively
contraindicated due to the physical size of the patient, in some
patients with syncope despite beta-blocker therapy, and in
patients with asthma or who are intolerant of beta-blockers.
Other therapies: Gene-speciﬁc LQTS therapies including oral
mexiletine [52], ﬂecainide [53], and ranolazine [54] have been
utilized to a limited extent in high-risk LQTS patients refractory to
beta-blockers or in patients with recurrent events despite ICD and
LCSD therapies. The use of these sodium channel blockers has
generally been limited to LQT3 patients. In brief, the use of these
agents is usually carried out on an observational trial basis, with,
occasionally, some dramatic results for individual subjects. Follow-up
experience with these therapies is limited. No general recommenda-
tions can be made at this time in the use of gene-speciﬁc therapies.3. Brugada Syndrome (BrS)
Expert Consensus Recommendations on Brugada Syndrome
Diagnosis
1. BrS is diagnosed in patients with ST-segment elevation with
type 1 morphology ≥2 mm in ≥1 lead among the right
precordial leads V1, V2, positioned in the 2nd, 3rd or 4th
intercostal space occurring either spontaneously or after
provocative drug test with intravenous administration of Class
I antiarrhythmic drugs.
2. BrS is diagnosed in patients with type 2 or type 3 ST-segment
elevation in ≥1 lead among the right precordial leads V1, V2
positioned in the 2nd, 3rd or 4th intercostal space when a pro-
vocative drug test with intravenous administration of Class I
antiarrhythmic drugs induces a type I ECG morphology.Expert Consensus Recommendations on Brugada Syndrome
Therapeutic Interventions
Class I
1. The following lifestyle changes are recommended in all
patients with diagnosis of BrS:
(a) Avoidance of drugs that may induce or aggravate ST-
segment elevation in right precordial leads (for
example, visit Brugadadrugs.org),
(b) Avoidance of excessive alcohol intake.
(c) Immediate treatment of fever with antipyretic drugs.
2. ICD implantation is recommended in patients with a diagnosis
of BrS who:
(a) Are survivors of a cardiac arrest and/or
(b) Have documented spontaneous sustained VT with or
without syncope.
Fig. 2. Consensus recommendations for ICDs in patients diagnosed with Brugada syndrome.
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3. ICD implantation can be useful in patients with a spontaneous
diagnostic type I ECG who have a history of syncope judged to
be likely caused by ventricular arrhythmias.
4. Quinidine can be useful in patients with a diagnosis of BrS and
history of arrhythmic storms deﬁned as more than two
episodes of VT/VF in 24 hours.
5. Quinidine can be useful in patients with a diagnosis of BrS:
(a) Who qualify for an ICD but present a contraindication
to the ICD or refuse it and/or
(b) Have a history of documented supraventricular
arrhythmias that require treatment.
6. Isoproterenol infusion can be useful in suppressing arrhythmic
storms in BrS patients.Class IIb
7. ICD implantation may be considered in patients with a
diagnosis of BrS who develop VF during programmed
electrical stimulation (inducible patients).
8. Quinidine may be considered in asymptomatic patients with a
diagnosis of BrS with a spontaneous type 1 ECG.
9. Catheter ablation may be considered in patients with a
diagnosis of BrS and history of arrhythmic storms or repeated
appropriate ICD shocks.Class III
10. ICD implantation is not indicated in asymptomatic BrS
patients with a drug-induced type 1 ECG and on the basis of
a family history of SCD alone.Epidemiology
No precise data are available on the epidemiology of BrS.
However, its prevalence is much higher in Asian and Southeast
Asian countries, especially Thailand, Philippines and Japan, reach-
ing 0.5–1 per 1000 [55]. In some part of Asia, BrS seems to be the
most common cause of natural death in men younger than 50
years. BrS is known as Lai Tai (Thailand), Bangungut (Philippines),
and Pokkuri (Japan). The reason for this higher prevalence in Asia
is unknown. However, it has been speculated that it may be in part
related to an Asian-speciﬁc sequence in the promoter region of
SCN5A [56].
BrS is 8–10 times more prevalent in males than in females [55].
The presence of a more prominent transient outward current
(Ito) in males may contribute to the male predominance of the
syndrome [57]. Higher testosterone levels also may have a sig-
niﬁcant role in the male predominance [58].
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Inheritance of BrS occurs via an autosomal dominant mode of
transmission. Twelve responsible genes have been reported so far [59].
In all 12 genotypes, either a decrease in the inward sodium or calcium
current or an increase in one of the outward potassium currents has
been shown to be associated with the BrS phenotype. Genetic
abnormalities are found in one third of genotyped BrS patients. SCN5A,
the gene that encodes for the α subunit of the cardiac sodium channel,
account for less than 30% of clinically diagnosed BrS patients. Genetic
testing is not recommended in the absence of a diagnostic ECG.
Genetic testing may be useful otherwise and is recommended for
family members of a successfully genotyped proband [1].
Clinical manifestations
Symptoms associated with BrS include:1. VF or aborted SCD (more often at night than during the day).
2. Syncope.
3. Nocturnal agonal respiration.
4. Palpitations.
5. Chest discomfort.
These symptoms often occur during rest or sleep, during a
febrile state or with vagotonic conditions, but rarely during
exercise. The syndrome typically manifests during adulthood, with
a mean age of sudden death of 41 7 15 years [55]. BrS is
associated with no clearly apparent structural heart diseases;
however, several clinical studies have reported mild right and left
ventricular structural abnormalities [60,61].
Diagnosis
Diagnostic criteria from the Report of the Second Consensus
Conference in 2005 have been used for the diagnosis of BrS [55].
Since some clinical studies on the sensitivity and the speciﬁcity of
the ECG diagnosis of BrS have been reported, new diagnostic
criteria of BrS are proposed here. BrS is deﬁnitively diagnosed
when a type I ST-segment elevation is observed either sponta-
neously or after intravenous administration of a sodium channel
blocking agent (ajmaline, ﬂecainide, pilsicainide, or procainamide)
in at least one right precordial lead (V1 and V2) [62], which are
placed in a standard or a superior position (up to the 2nd
intercostal space) [63,64].
The differential diagnosis includes a number of diseases and
conditions that can lead to Brugada-like ECG abnormality, including
atypical RBBB, left ventricular hypertrophy, early repolarization, acute
pericarditis, acute myocardial ischemia or infarction, acute stroke,
pulmonary embolism, Prinzmetal angina, dissecting aortic aneurysm,
various central and autonomic nervous system abnormalities, Duch-
enne muscular dystrophy, thiamine deﬁciency, hyperkalemia, hyper-
calcemia, arrhythmogenic right ventricular cardiomyopathy (ARVC),
pectus excavatum, hypothermia, and mechanical compression of the
right ventricular outﬂow tract (RVOT) as occurs in mediastinal tumor
or hemopericardium [55,65].
Many subjects displaying a type 1 ECG, spontaneous or drug-
induced, are asymptomatic. In asymptomatic patients, the follow-
ing ﬁndings are considered supportive for the diagnosis of BrS:1. Attenuation of ST-segment elevation at peak of exercise stress
test followed by its appearance during recovery phase [66,67].
It should be noted, however, that in selected BrS patients,
usually SCN5A mutation-positive patients, it has been observed
that ST-segment elevation might become more evident during
exercise [66].2. Presence of ﬁrst-degree AV block and left-axis deviation of
the QRS.3. Presence of atrial ﬁbrillation.
4. Signal-averaged ECG; late potentials [68].
5. Fragmented QRS [69,70].
6. ST-T alternans, spontaneous LBBB ventricular premature beats
(VPB) during prolonged ECG recording.
7. Ventricular ERP o200 ms recorded during EPS [70,71] and HV
interval 460 ms.
8. Absence of structural heart disease including myocardial
ischemia.
Prognosis and risk stratiﬁcation
Since the ﬁrst reporting, the reported annual rate of events has
decreased [70,72–78]. The change probably reﬂects the inherent
bias during the ﬁrst years following the description of a novel
disease, in which particularly severe forms of the disease are most
likely to be diagnosed.
Several clinical variables have been demonstrated to predict a
worse outcome in patients with BrS. Little controversy exists on
the high risk of recurrence of cardiac arrest among patients who
have survived a ﬁrst VF. There is general agreement that these
patients should be protected with an ICD, irrespective of the
presence of other risk factors [55].
Most studies have concurrently agreed on the evidence that the
presence of syncopal episodes in patients with a spontaneous
type I ECG at baseline (without conditions known to unmask the
signature sign, i.e., drugs and fever) have high risk of cardiac
arrhythmic events at follow-up [70,72–80].
Among other risk stratiﬁcation indicators, the presence of
fragmented QRS [69,70] and an effective refractory period below
o200 ms [70,71] have been recently proposed. Male gender has
consistently been shown to be associated with more arrhythmic
events [81]. Spontaneous AF, which can appear in 10% to 53% of
cases, has been shown to have prognostic signiﬁcance and has
been associated with a higher incidence of syncopal episodes and
documented VF [82,83].
The risk of lethal or near-lethal arrhythmic episodes among
previously asymptomatic patients with BrS varies according to the
series: 8% event rate at 33 7 39 months of follow-up reported by
Brugada et al [73]; 6% event rate at 34 7 44 months by Priori et al
[70]; 1% event rate after 40 7 50 months and 30 7 21 months of
follow-up, respectively, by Eckardt et al [76] and Giustetto et al [84],
and, ﬁnally, Probst et al [85] reported a 1.5% event rate at 31 months of
follow-up.
Although large registries agree that EPS inducibility is greatest
among BrS patients with previous sudden death or syncope [75,76],
there is no consensus on the value of the EPS in predicting outcome.
The results published by Brugada et al [73] indicate that inducibility
during EPS is an independent predictor for arrhythmic events, and
Giustetto et al [84] stressed the negative predictive value (none of
the patients with a negative EPS developed arrhythmic events vs
15% of patients with a positive EPS result during 30 7 21 months of
follow-up), while the rest of the registries failed to demonstrate this
[75,76,85]. The PRELUDE (PRogrammed ELectrical stimuLation pre-
Dictive valuE) registry failed to support the view that lack of
inducibility has negative predictive value in BrS [70]. The FINGER
(France, Italy, Netherlands, GERmany) registry, the largest series of
BrS patients published so far, found that inducibility of sustained
ventricular arrhythmias was signiﬁcantly associated with a shorter
time to ﬁrst arrhythmic event in the univariate analysis, but in the
multivariate analysis, inducibility did not predict arrhythmic events
[85]. These results were conﬁrmed in a recent prospective study in
previously asymptomatic patients [70]. Neither a positive family
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risk marker in any of the large studies [75,76,81]. However, some
speciﬁc types of mutations, such as those that result in a truncated
protein, or some common SNPs, might have prognostic signiﬁcance
[86–89].
Therapeutic options and recommendations for BrS patients
ICD (Fig. 2)
To date, the only proven effective therapeutic strategy for the
prevention of SCD in BrS patients is the ICD. It is important to remark
that ICDs are not free from several disadvantages, especially in the
group of patients who are active young individuals, who will require
multiple device replacements during their life-time. Some series
have reported low rates of appropriate shocks (8%–15%, median
follow-up 45 months) and high rates of complications, mainly
inappropriate shocks (20%–36% at 21–47 months follow-up)
[2,90,91]. Asymptomatic BrS patients do not qualify for an ICD as
their risk for life-threatening events is very low [59]. In this group of
patients, individual assessment of associated risk factors (gender, age,
baseline ECG, inducibility) should be performed.
Pharmacological treatment in BrS
With the objective of rebalancing the ionic currents affected in
BrS during the cardiac action potential, drugs that inhibit the
transient outward potassium current (Ito) or increase the sodium+
and calcium currents have been tested in BrS: Isoproterenol (which increases the L-type calcium current), has
proved to be useful for treatment of electrical storm in BrS [92],
but controlled data on its therapeutic role are not available. Quinidine, a Class Ia antiarrhythmic drug with Ito and IKr
blocker effects, has been shown to prevent induction of VF
and suppress spontaneous ventricular arrhythmias in a clinical
setting. Quinidine is currently being used in (1) patients with
ICD and multiple shocks; (2) cases in which ICD implantation is
contraindicated; or (3) for the treatment of supraventricular
arrhythmias [93]. It has been suggested that quinidine could
also be useful in children with BrS, as a bridge to ICD or as an
alternative to it [94,95]. Randomized studies on the use of
quinidine, however, have not been performed.
Radiofrequency catheter ablation in BrS
After the demonstration that VF events were triggered by
ventricular ectopy of similar morphology, radiofrequency ablation
of ventricular ectopy has been postulated as a therapeutic
approach in BrS patients. Few anecdotal cases in high-risk BrS
implanted with an ICD have shown no short-term recurrence of
VF, syncope or SCD [96–99]. Nademanee et al [100] have presented
the ﬁrst series showing that electrical epicardial substrate ablation
in the RVOT can prevent VF inducibility in a high-risk population.
However, randomized data on the effect of catheter ablation on
spontaneous arrhythmic events are lacking.
4. Catecholaminergic Polymorphic Ventricular Tachycardia
(CPVT)Expert Consensus Recommendations on CPVT Diagnosis
1. CPVT is diagnosed in the presence of a structurally normal
heart, normal ECG, and unexplained exercise or
catecholamine-induced bidirectional VT or polymorphic
ventricular premature beats or VT in an individual o40 years
of age.Expert Consensus Recommendations on CPVT Diagnosis
2. CPVT is diagnosed in patients (index case or family member)
who have a pathogenic mutation.
3. CPVT is diagnosed in family members of a CPVT index case
with a normal heart who manifest exercise-induced PVCs or
bidirectional/polymorphic VT.
4. CPVT can be diagnosed in the presence of a structurally normal
heart and coronary arteries, normal ECG, and unexplained
exercise or catecholamine-induced bidirectional VT or
polymorphic ventricular premature beats or VT in an
individual 440 years of age.Expert Consensus Recommendations on CPVT Therapeutic
Interventions
Class I
1. The following lifestyle changes are recommended in all
patients with diagnosis of CPVT:
(a) Limit/avoid competitive sports,
(b) Limit/avoid strenuous exercise,
(c) Limit exposure to stressful environments.
2. Beta-blockers are recommended in all symptomatic patients
with a diagnosis of CPVT.
3. ICD implantation is recommended in patients with a diagnosis
of CPVT who experience cardiac arrest, recurrent syncope or
polymorphic/bidirectional VT despite optimal medical
management, and/or LCSD.Class IIa
4. Flecainide can be a useful addition to beta-blockers in patients
with a diagnosis of CPVT who experience recurrent syncope or
polymorphic/bidirectional VT while on beta-blockers.
5. Beta-blockers can be useful in carriers of a pathogenic CPVT
mutation without clinical manifestations of CPVT (concealed
mutation-positive patients).Class IIb
6. LCSD may be considered in patients with a diagnosis of CPVT
who experience recurrent syncope or polymorphic/
bidirectional VT/several appropriate ICD shocks while on beta-
blockers and in patients who are intolerant or with
contraindication to beta-blockers.Class III
7. ICD as a standalone therapy is not indicated in an
asymptomatic patient with a diagnosis of CPVT.
8. Programmed electrical stimulation is not indicated in CPVT
patients.Introduction
CPVT is a rare arrhythmogenic disorder characterized by
adrenergic-induced bidirectional and polymorphic VT [101,102].
Epidemiology
The prevalence of the disease could be as high as 0.1:1000.
However, the number is a rough estimate and is not derived
from a systematic assessment in the population. Given that the
resting ECG is normal in CPVT patients and cardiac imaging is also
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in the population. As a result, the real prevalence of the disease is
unknown.
Genetic variants
Two types of CPVT have been identiﬁed: an autosomal domi-
nant form, due to mutations in the gene encoding for the cardiac
ryanodine receptor (RyR2) [103,104] known as CPVT1, and a less
common autosomal recessive form, resulting from mutations in
the gene for cardiac calsequestrin (CASQ2) [105,106], now known
as CPVT2. Altogether mutations in RyR2 [107] and CASQ2 are found
in only 60% of the CPVT patients [1], suggesting that other genes
may be involved in CPVT.
Mutations in the KCNJ2 gene encoding the cardiac inward
rectiﬁer K channel are known to cause the Andersen-Tawil
syndrome, also known as LQT7. Mutations in this gene have
recently been found in patients with adrenergically mediated
bidirectional VT. It is currently unknown whether these cases
should be regarded as variants of LQT7 that phenocopy CPVT or
whether speciﬁc mutations in the KCNJ2 gene cause a novel
variant of CPVT [108]. In 2007 a consanguineous Arab family with
an early-onset lethal form of recessive CPVT was linked to a new
locus on chromosome 7p1422-p22; until now, however, no gene
has been identiﬁed [109].
Mutations in the Ank2 gene are known to cause LQT4. Recently,
mutations in this gene have also been described in a patient with
bidirectional VT [110]. In analogy to the discussion about the
mutations in the KCNJ2 gene, it is unclear whether Ank2 should be
regarded as a CPVT gene or whether LQT4 may phenocopy CPVT.
Three mutations with recessive inheritance were recently identi-
ﬁed in two families with cardiac arrhythmias and sudden death
[111]. However, more data are required before it becomes estab-
lished whether TRDN, which encodes triadin, is a gene for this
novel form of recessive CPVT. Finally, a mutation in the CALM1
gene encoding for calmodulin kinase has been observed co-
segregating with adrenergically mediated arrhythmias in one large
family, and a second mutation in the same gene was found in a
sporadic patient with CPVT diagnosis [112].
Clinical manifestations
The ﬁrst clinical episode often manifests in the ﬁrst or second
decade of life and is usually prompted by physical activity or
emotional stress [102,113,114]. When the fainting episode is
associated with seizure-like activity it may be attributed to a
neurologic diagnosis, thus causing delay in the diagnosis of CPVT.
A family history of exercise-related syncope, seizure or sudden
death is reported in 30% of the patients and may help directing
diagnosis toward CPVT.
Diagnosis
CPVT patients present a normal resting ECG, occasionally with a
lower than normal heart rate [102,115]. When patients start
exercising ventricular ectopy develops, increasing in complexity as
the heart rate increases. Indeed, initially monomorphic VPBs appear
and they may be followed by polymorphic VPBs and bidirectional or
polymorphic VT. Holter monitoring, exercise stress test or implan-
table loop recorders are therefore pivotal investigations for estab-
lishing the diagnosis of CPVT. Adrenergically mediated atrial
arrhythmias (premature atrial beats, atrial tachycardias and atrial
ﬁbrillation) are also common manifestations of the disease.
Programmed electrical stimulation has no diagnostic or prog-
nostic value in CPVT as either bidirectional or polymorphic VT is
not inducible. Drug challenge with epinephrine or isoproterenolmay elicit arrhythmias and is useful in patients who are unable to
exercise (for example, after resuscitation or because of young age).
Exercise-induced atrial arrhythmias, including atrial ﬁbrillation,
are part of the clinical phenotype of CPVT [116,117].
Risk stratiﬁcation
There are not many indicators of risk of adverse outcome in CPVT.
The occurrence of cardiac arrest before diagnosis, but not the
occurrence of syncope, is associated with higher risk of arrhythmic
episodes at follow-up [115]. Similarly, diagnosis in childhood is a
predictor of adverse outcome. After diagnosis, the lack of beta-
blocker therapy and the use of beta-blockers other than nadolol are
independent predictors for arrhythmic events [115]. Also, the persis-
tence of complex ectopy in exercise tests is a marker for worse
outcome [115]. Initial evidence of genotype–phenotype correlations
are emerging in CPVT patients. Relatives with a RYR2 mutation in the
C-terminal channel-forming domain showed an increased odds of
nonsustained VT (odds ratio, 4.1; 95% CI, 1.5–11.5; P ¼ .007)
compared with N-terminal domain [118]. In the recessive form of
CPVT, affected individuals carry homozygous or compound hetero-
zygous mutations; the carriers of a single CASQ2 mutation are
healthy [119]. Nevertheless, several clinical investigations suggested
that a single CASQ2 mutation could represent a potential suscept-
ibility factor for ventricular arrhythmias [120–122].
Management
Beta-blockers
The ﬁrst-line therapeutic option for patients with CPVT is beta-
blockers without intrinsic sympathomimetic activity combined
with exercise restriction.
Nadolol, being a long-acting drug, is preferred for prophylactic
therapy and has been found to be clinically effective. The dosage used
is usually high (1–2 mg/kg) with the necessity of a faultless
compliance to the therapy. The annual rate of arrhythmic events on
beta-blockers ranges between 11% per year to 3% per year (27% over
8 years) [115]. Larger groups of CPVT probands are needed to address
the issue of beta-blocker efﬁcacy in CPVT. As nadolol is not available
in several countries it may be suggested that other nonselective beta-
blockers are equally effective (i.e., propranolol). Holter recordings and
exercise tests should be repeated periodically to assure that the
degree of sinus tachycardia that precedes onset of arrhythmias is
known so that in daily life it can be avoided as much as possible.
Moreover, to prevent noncompliance-related SCD, it is crucial to alert
the patients of the importance of adherence to therapy to preempt
life-threatening events.
Asymptomatic VPBs usually persist on Holter recordings (and
exercise tests) with an unmodiﬁed threshold of appearance. Complete
suppression of asymptomatic VPBs does not seem to be mandatory.
The presence of couplets or more successive VPBs during exercise
testing seems signiﬁcantly associated with future arrhythmic events,
suggesting intensifying the treatment in these patients [115].
ICD
An ICD should be considered in CPVT patients who do not
respond to an optimal medical management and when LCSD is not
possible. All efforts should be made to ensure that patients with an
ICD have also an optimal medical treatment [123,124]. In patients
who have experienced an aborted cardiac arrest before initiation
of therapy, beta-blockers, or beta-blockers and ﬂecainide, should
be started and ICD implanted.
Implantation of an ICD is a technical challenge in pediatric patients,
and problems such as inappropriate shocks, proarrhythmic effects of
the ICD and the need for a life-time protection requiring multiple
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Painful shocks by ICD can increase the sympathetic tone and trigger
further arrhythmias leading to a malignant cycle of ICD shocks and
even death. Because of this the ICD should be programmed with long
delays before shock delivery and high cutoff rates.
Verapamil
Verapamil has been shown to be beneﬁcial in some CPVT
patients by reducing the ventricular arrhythmia burden on top of
beta-blocker therapy during a short-term follow-up period
[125,126], though its long-term effect remains controversial.
Flecainide
Flecainide reduces signiﬁcantly the ventricular arrhythmia
burden in a limited number of CPVT patients [127,128]. A larger
study is required to fully elucidate the effect of the drug, but
ﬂecainide should now be regarded as the ﬁrst addition to beta-
blockers when control of arrhythmias seems incomplete.
Left cardiac sympathetic denervation (LCSD)
Small series have been published reporting signiﬁcant results of
LCSD on arrhythmic events [50,51,129–133]. Although the short-term
results seem encouraging, more data with a long-term follow-up are
needed. LCSD is not available in many centers all over the world as it
requires a very well-trained surgeon and dedicated techniques. There-
fore, the place of LCSD in the therapeutic management of CPVT
patients resistant to optimal pharmacological therapy remains to be
proven but seems very promising.
Catheter ablation
Catheter ablation of the bidirectional VPBs that trigger VF may
become an adjunctive therapy in patients with refractory CPVT.
However, the published experience is very limited and therefore is
not discussed in the recommendation [134].
Evaluation of family members
Family screening (siblings and parents) by clinical evaluation
and genetic testing (when a mutation has been detected) is
mandatory to identify undiagnosed patients and asymptomatic
carriers who are at risk of arrhythmic events and should be treated.
It is suggested that genetically positive family members should
receive beta-blockers even after a negative exercise test [115,118].5. Short QT Syndrome (SQTS)Expert Consensus Recommendations on Short QT Syndrome
Diagnosis
1. SQTS is diagnosed in the presence of a QTc ≤330 ms.
2. SQTS can be diagnosed in the presence of a QTc o360 ms and
one or more of the following: a pathogenic mutation, family
history of SQTS, family history of sudden death at age ≤40,
survival of a VT/VF episode in the absence of heart disease.Expert Consensus Recommendations on Short QT Syndrome
Therapeutic Interventions
Class I
1. ICD implantation is recommended in symptomatic patients
with a diagnosis of SQTS who
(a) Are survivors of a cardiac arrest and/or(b) Have documented spontaneous sustained VT with or
without syncope.Class IIb
2. ICD implantation may be considered in asymptomatic patients
with a diagnosis of SQTS and a family history of SCD.
3. Quinidine may be considered in asymptomatic patients with a
diagnosis of SQTS and a family history of SCD.
4. Sotalol may be considered in asymptomatic patients with a
diagnosis of SQTS and a family history of SCD.Epidemiology and genetic bases
One of the rarer cardiac channelopathies is the short QT
syndrome (SQTS). As the terminology implies the signature sign
of this disease entity is a short QT interval. Gussak et al [135] were
the ﬁrst to suggest an association with atrial and ventricular
ﬁbrillation (i.e., SCD). With more case reports halfway through
the ﬁrst decade of this century this association became clearer
[136–138], but more than 10 years after the ﬁrst description, the
largest series described contain at most 60 cases, underlining the
fact that the disease entity is rare indeed [139]. Until now DNA
variants in 3 potassium channel genes (KCNH2, KCNQ1, KCNJ2)
have been described to associate with SQTS [137,138,140]; inter-
estingly mutations in these three genes are also linked with three
variants of LQTS (LQT1 ,LQT2, and LQT7, respectively). While
mutations found in the three genes in LQTS patients cause a loss
of the protein function, the mutations found in SQTS patients
cause a gain of function. Mutations in the genes encoding alpha-
and beta-subunits of the L-type cardiac calcium channel (CACNA1C
and CACNB2) have been identiﬁed in patients with short QT
interval. Often patients with mutations in these genes present a
type I Brugada syndrome ECG either spontaneously or in response
to drug challenge with Class I antiarrhythmic agents [141].
Clinical diagnosis
The diagnosis of SQTS is still a matter of debate. A major point
of discussion in the deﬁnition of diagnostic criteria is represented
by the cutoff value at the lower end of the QTc that should be used
to diagnose the disease. QTc should be calculated avoiding tachy-
cardia and bradycardia to prevent the use Bazett’s formula at rates
in which its correction is not linear and may lead to under-
estimation or overestimation of QTc values.
The proposed diagnostic scoring scheme that has been put
forward by Gollob et al [142], has not been accepted unanimously
[143,144]. In analogy to the Schwartz score for the LQTS the score
uses a number of clinical criteria with a gradual score for the QTc
interval and a signiﬁcant role for clinical and genetic criteria.
This group has reached a consensus that a cutoff value ≤330 ms
should be used for the diagnosis. Gollob et al [142] in their
“diagnostic score” also used 330 ms as the cutoff with the heaviest
weight. This QTc value is well below the 2 standard deviations
(7350 ms in males and 7365 ms in females) [145–147]. In the
Finnish cohort reported by Anttonen et al [148] only 0.4% of
individuals had a QTc o340 ms and 0.1% of the population had a
QTc o320 ms.
Risk stratiﬁcation and treatment
Therapeutic management using ICDs is undisputed in SQTS
patients who have experienced sustained VT/VF episodes [139].
Appropriate programming of the ICD is needed to prevent
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waves. Quinidine seems an effective alternative due to the QT-
prolonging action. However, it has been reported that the QTc-
prolonging effect of quinidine is particularly prominent in patients
with a KCNH2 mutation (SQTS type 1) [139,149]. Other drugs,
including Class III drugs, such as sotalol, are not effective in
prolonging the QTc interval in SQT1 patients [149] but may be
effective in the other subtypes.
The optimal strategy for primary prevention of cardiac arrest in
SQTS is not clear given the lack of independent risk factors, including
syncope, for cardiac arrest. Although intuitively it might seem
reasonable to suggest that patients with the shortest QTc values
are at highest risk, clinical data do not support this hypothesis [139].
However, in a combined symptomatic and asymptomatic group (QTc
o360 ms) QTc was the only risk factor for arrhythmic events [139].
Quinidine might have a role in primary prevention of cardiac
arrest, but data are very preliminary and require conﬁrmation in larger
cohorts of patients. There are certainly no data to support the
implantation of an ICD in asymptomatic patients with SQTS. A study
from Finland revealed that individuals with short (o340ms) and very
short (o320 ms) QTc values had no documented arrhythmic events
after an average follow-up of 29 years [148]. Data from Japan and the
US seem to support these ﬁndings [145,150]. An ICD might be
considered in SQTS patients with a strong family history of SCD and
evidence for abbreviated QTc in at least some of the victims.6. Early Repolarization (ER)Expert Consensus Recommendations on Early Repolarization
Diagnosis
1. ER syndrome is diagnosed in the presence of J-point elevation
≥1 mm in ≥2 contiguous inferior and/or lateral leads of a
standard 12-lead ECG in a patient resuscitated from otherwise
unexplained VF/polymorphic VT
2. ER syndrome can be diagnosed in an SCD victim with a
negative autopsy and medical chart review with a previous
ECG demonstrating J-point elevation ≥1 mm in ≥2 contiguous
inferior and/or lateral leads of a standard 12-lead ECG
3. ER pattern can be diagnosed in the presence of J-point
elevation ≥1 mm in ≥2 contiguous inferior and/or lateral leads
of a standard 12-lead ECGExpert Consensus Recommendations on Early Repolarization
Therapeutic Interventions
Class I
1. ICD implantation is recommended in patients with a diagnosis
of ER syndrome who have survived a cardiac arrest.Class IIa
2. Isoproterenol infusion can be useful in suppressing electrical
storms in patients with a diagnosis of ER syndrome.
3. Quinidine in addition to an ICD can be useful for secondary
prevention of VF in patients with a diagnosis of ER syndrome.Class IIb
4. ICD implantation may be considered in symptomatic family
members of ER syndrome patients with a history of syncope in
the presence of ST-segment elevation 41 mm in 2 or more
inferior or lateral leads.5. ICD implantation may be considered in asymptomatic
individuals who demonstrate a high-risk ER ECG pattern (high
J-wave amplitude, horizontal/descending ST segment) in the
presence of a strong family history of juvenile unexplained
sudden death with or without a pathogenic mutation.Class III
6. ICD implantation is not recommended asymptomatic patients
with an isolated ER ECG pattern.Deﬁnition and epidemiology
In 1953, Osborn described the classic J wave in experimental
hypothermia [151]. Dogs subjected to hypothermia developed
spontaneous VF that was preceded by the development of J waves
[151]. The J wave, which was attributed to a current of injury
(hence the term “J”) was later termed the Osborn wave. Further
experiments demonstrated that hypothermic J waves are presum-
ably the ECG reﬂection of increased dispersion of repolarization
caused by a disproportionate abbreviation of the epicardial action
potential compared to the endocardium [152].
ER is a common ECG pattern characterized by J-point and
ST-segment elevation in 2 or more contiguous leads. The presence
of ER pattern in the precordial leads has been considered a benign
phenomenon, but recently its presence in the inferior and/or
lateral leads has been associated with idiopathic VF in case-
control studies (ER syndrome) [153–158]. Furthermore, the ER
ECG pattern is associated with an increased risk of arrhythmic
death and mortality in epidemiological studies, either as a primary
cause of sudden death or in conjunction with concurrent cardiac
disease [159–162].
Numerous cases of patients with idiopathic VF who have the ER
pattern in the inferior and/or lateral ECG leads have now been
described. At least ﬁve case-control studies assessing the presence
of ER among patients with idiopathic VF, involving more than 300
patients, have been published [153–158].
ER ECG pattern (41 mm) in the inferior/lateral leads occurs in
1%–13% of the general population and in 15%–70% of idiopathic VF
cases [153–161]. In the pediatric age group it is even more
prevalent. Male sex is strongly associated with ER ECG pattern,
since over 70% of subjects with ER are males. The prevalence of the
ER ECG pattern declines in males from early adulthood until
middle age, which suggests a hormonal inﬂuence on the presence
of ER [163]. The ER pattern is more common in young physically
active individuals, athletes, and African-Americans [164]. There is
an increased prevalence of ER reported in Southeast Asians [161].
The ER pattern is associated with high vagal tone, as well as
hypothermia and hypercalcemia. ECG features of bradycardia,
prolonged QRS duration, short QT interval, and left ventricular
hypertrophy assessed by the Sokolow-Lyon index are also asso-
ciated with ER [163]. There also is some overlap between the BrS
and ER syndrome, since an ER pattern in the inferior or lateral
leads is found in 11%–15% of the BrS patients [165]. ER pattern also
is frequently observed in patients with short QT syndrome, and
many patients with an ER pattern or ER syndrome have a relatively
short QT interval without frank short QT syndrome [166].
Clinical diagnosis
Given the high prevalence of the ECG pattern of ER, we
recommend a conservative approach in establishing the diagnosis
of this condition. Patients with the ER pattern on the 12-lead ECG
who have been resuscitated from an ECG-documented episode of
idiopathic VF and/or polymorphic VT are those diagnosed with the
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an archived ECG showing the ER pattern also are diagnosed with
ER syndrome when evidence of other diagnoses such as BrS have
been excluded.
At this stage of our understanding of early repolarization, there
is an unusual dilemma in which the ECG pattern is highly
prevalent, the inheritance is not clearly monogenic in most cases
and the genetic substrate is not clearly deﬁned. For this reason, we
have chosen not to label family members with the ER pattern as ER
syndrome patients pending a better understanding of their risk.
High-risk features including extent of family history of SCD,
arrhythmic syncope and amplitude and morphology of the ER
pattern may lead to consideration of a prophylactic ICD in
conjunction with review by an expert center with a focus on
inherited arrhythmias. Asymptomatic individuals with the ER
pattern on ECG with a mutation considered pathogenic for ER as
well as family members of a patient diagnosed with ER syndrome
who present with a diagnostic ECG may be affected by the disease.Genetic variants
Genetic contributions to ER are suggested by anecdotal obser-
vations of a common familial history of SCD of subjects with ER
and idiopathic VF [167]. Familial ER has been reported to have an
autosomal dominant inheritance pattern with incomplete pene-
trance. Two independent population-based studies also have
suggested some degree of inheritance of the ER patterns in the
general population [163,168], but the familial inheritance of
malignant ER patterns has not been clearly demonstrated [153].
A candidate gene approach in idiopathic VF patients with ER has
identiﬁed a mutation in KCNJ8, which encodes a pore-forming
subunit of the ATP-sensitive potassium channel [169,170]. Muta-
tions in the L-type calcium channel genes, including CACNA1C,
CACNB2B, and CACNA2D1, [171] as well as loss-of-function muta-
tions in SCN5A [172] have also been associated with idiopathic VF
with ER. Given the high prevalence of ER in the general popula-
tion, ER likely has a polygenic basis that also is inﬂuenced by
nongenetic factors. A recent genome-wide association meta-
analysis in three independent populations of European ancestry
found eight loci associated with ER, the strongest association being
found with SNPs located at the KCND3 genes, which encode the
transient outward potassium channel Ito (Kv4.3) coding gene
[173]. However, replication studies could not conﬁrm these obser-
vations in other populations so far.Clinical manifestations
Life-threatening arrhythmias are often the ﬁrst and unexpected
manifestation of ER syndrome. An increase in the amplitude of ER has
been described before the onset of VF in ER syndrome patients, and
VF is usually triggered by short-long-short sequence in which a short
coupled extrasystolic beat is followed by a pause and the next
extrasystolic beat falls on the T wave of the preceding beat and
initiates the arrhythmic episode [156]. The majority of population-
based studies have shown that subjects with ER in the inferior leads
are at a higher risk of all-cause mortality, cardiac mortality, and
especially unexpected sudden death [159–162], though some excep-
tions have been reported [174]. In the studies of middle-aged
subjects, the mortality curves of subjects with and without ER begin
to diverge after age 50 [159,160], suggesting that the presence of the
ER pattern may increase the risk of arrhythmic death in the presence
of additional triggers, such as acute ischemic events.Diagnosis
In survivors of VF and in patients with polymorphic VT, clinical
evaluation including echocardiogram, coronary angiography, mag-
netic resonance imaging (MRI), and selected endocardial biopsies
should be performed to exclude other causes of VF. Consideration
should be given to provocative drug infusion with epinephrine and
with a sodium channel blocker, such as ajmaline or ﬂecainide, to
unmask latent inherited causes of cardiac arrest, such as BrS and
LQTS [157]. The presence of short QT syndrome also should be
noted. There are no validated techniques to provoke the ER
pattern, although 12-lead Holter monitoring to detect evidence
of the ER pattern during bradycardia is warranted.Risk stratiﬁcation
The magnitude of the J-point elevation may have prognostic
signiﬁcance. Either slurred or notched J-point elevation ≥0.2 mV is
relatively rare in the general population but appears to be
associated with an increased risk [159]. Furthermore, J-point
elevation in idiopathic VF patients is of greater amplitude and
ECG lead distribution compared to those with an established cause
of cardiac arrest [157]. The available data also suggest that
transient changes in the presence and amplitude of J-point
elevation portends a higher risk for VF [153]. A horizontal or
descending ST segment following J-point elevation is associated
with a worse outcome in the general population [175]. This
observation has been very helpful in distinguishing idiopathic VF
patients from matched controls and is a key aid in clinical decision
making [176].Management
The clinical implications of the observation of an ER pattern in the
ECG of an asymptomatic subject are not clear. The presence of ER is
associated with 3 times the risk of developing VF, but the overall risk is
still negligible considering the rarity of VF in the general population
[158,177]. Because the presence of ERmay increase the vulnerability to
sudden death during an acute ischemic event, a plausible implication
stemming from the population studies is that middle-aged subjects
with the ER pattern in the ECG, especially those with a high amplitude
of J-point elevation and horizontal/downsloping ST segment, should
target a reduction in their long-term risk for acute coronary events in
accordance with current practice guidelines.
Electrical storm is relatively common after ICD implantation in
patients with the ER syndrome [178,179]. Case series evidence
supports the acute use of isoproterenol for suppression of recurrent
VF and quinidine for long-term suppression [178,179]. Isoproterenol
is typically initiated at 1.0 μg/min, targeting a 20% increase in heart
rate or an absolute heart rate 490 bpm, titrated to hemodynamic
response and suppression of recurrent ventricular arrhythmia.Screening of family members
No recommendations can be given to screen the families of
individuals with asymptomatic ER pattern. There are no established
provocative tests to diagnose concealed ER in family members of ER
syndrome patients, although preliminary observations suggest that
the Valsalva maneuver may assist in identifying concealed ER cases.
Therapeutic recommendation 5 uses the term “strong family
history.” There is no clear deﬁnition of this term, but it is typically
chosen when more than one family member is affected, deaths
occur at an early age and a ﬁrst-degree relative is affected.
S.G. Priori et al. / Journal of Arrhythmia 30 (2014) 1–28147. Progressive Cardiac Conduction Disease (PCCD)Expert Consensus Recommendations on Progressive Cardiac
Conduction Disease Diagnosis
1. Progressive cardiac conduction disease (PCCD) is diagnosed in
the presence of unexplained progressive conduction
abnormalities in young (o50 years) individuals with
structurally normal hearts in the absence of skeletal
myopathies, especially if there is a family history of PCCD.Expert Consensus Recommendations on Progressive Cardiac
Conduction Disease Therapeutic Interventions
Class I
1. Pacemaker implantation is recommended in patients with a
diagnosis of PCCD and the presence of:
(a) Intermittent or permanent third-degree or high-grade
AV block or
(b) Symptomatic Mobitz I or II second-degree AV block.Class IIa
2. Pacemaker implantation can be useful in patients with a
diagnosis of PCCD and the presence of bifascicular block with
or without ﬁrst-degree AV block.
3. ICD implantation can be useful in adult patients diagnosed
with PCCD with a mutation in the lamin A/C gene with left
ventricular dysfunction and/or nonsustained VT.Introduction
Progressive cardiac conduction disease (PCCD) is a heterogeneous
disorder of unclear etiology, which can be serious and potentially
life-threatening. Its underlying mechanism can be either functional
or structural or there can be overlap between these two mechanisms
[180]. The most frequent form of PCCD is a degenerative form called
Lenègre-Lev disease. The mechanism of PCCD with structural
abnormality is considered as a primary degenerative disease or an
exaggerated aging process, with sclerosis principally affecting the
conduction tissue [181]. Aging itself is suggested to play a critical role
in PCCD, meaning that at every age conduction abnormalities are
more outspoken than expected based on age alone.
Both familial PCCD with either a structurally normal heart
(hereby deﬁned as “isolated PCCD”) and familial PCCD associated
with dilated cardiomyopathy will be discussed.Epidemiology
No systematic clinical data are available on the age of onset and
course of symptoms in affected individuals. When genetically
mediated, the majority of PCCD patients have an autosomal
dominant mode of inheritance [1].Genetic variants
The discovery of gene mutations that are causally involved in
inherited PCCD is relatively recent [180]. Common PCCD-
associated genes (deﬁned as genes with causative mutation in
45% of affected individuals [1]) are SCN5A and TRPM4 for PCCD
occurring in the structurally intact heart [182] and LMNA for PCCD
associated with heart failure [1].PCCD and structurally normal heart
Mutations in the SCN5A gene cause the majority of familial PCCD
and often causes a combined phenotype with Brugada syndrome
[181]. Subtle structural abnormalities, mainly ﬁbrosis, are present in
SCN5Amutation positive subjects. Recently, mutations in the transient
receptor potential channel, subfamily M (elastatine), member 4
(TRPM4) Ca2+-activated channel gene were reported in patients with
PCCD [183] and are estimated to account for a signiﬁcant portion of
inherited forms of RBBB (25%) or AV block (10%) [1].
PCCD and structurally abnormal heart
When PCCD is accompanied by the presence of concomitant
congenital heart disease, mutations in early cardiac transcription
factor genes such as Nkx2.5 or GATA4 are more likely. Mutations in
Nkx2.5 or TBX5, genes involved in the regulation of heart devel-
opment, are associated with structural congenital heart defects
such as septal defects [181].
PCCD also may precede development of dilated cardiomyopa-
thy. Mutations in the LMNA gene encoding lamin A/C were found
to be causally involved in Emery-Dreifuss muscular dystrophy as
well as in families with dilated cardiomyopathies and severe PCCD
without skeletal muscle involvement [180,181,184].
In a small percentage of cases, Wolff-Parkinson-White
syndrome is familial and associated with cardiac hypertrophy,
presenting as a hypertrophic cardiomyopathy phenocopy. Muta-
tions in the PRKAG2 gene and other glycogen storage diseases may
also display abnormal electrical AV connections. Patients with
mutations in the PRKAG2 gene have a variable combination of
glycogen storage cardiomyopathy, PCCD including sinus bradycar-
dia and AV block, ventricular preexcitation, arrhythmias, and
sudden death [185]. Most authors would classify the phenotype
of PRKAG2 mutations as a hypertrophic cardiomyopathy with
conduction defects rather than a PCCD with hypertrophy.
Clinical manifestations
PCCD can be seen by a prolonged P-wave duration, PR interval
and QRS widening with axis deviation on the surface ECG, which
may progress over time as an age-dependent penetrance. In
isolated forms of PCCD, there are typically no extracardiac man-
ifestations. In nonisolated forms of PCCD, congenital heart disease,
cardiomyopathy, or extracardiac manifestations are present. Phe-
notypic expression of mutations may vary from individual to
individual and has, among others, an age-dependent onset [1].
In patients with mutations in the LMNA gene and PCCD, the AV
node and specialized conduction system are progressively
replaced by ﬁbrofatty tissue and patients are at risk for premature
SCD [184,185]. In addition to conduction abnormalities, most adult
patients with LMNA mutations have AV conduction disturbances,
and atrial and ventricular arrhythmias [186]. LMNA mutations are
also found at frequencies of 6%–8% among patient populations
with idiopathic or familial dilated cardiomyopathy. Heart failure is
a common phenotypic feature in families with cardiac manifesta-
tions of LMNA disease [187,188]. Because of the limited informa-
tion and the low number of patients in many of the clinical
reports, a statement about the incidence of arrhythmias in relation
to structural or functional PCCD is precarious. The occurrence of
tachyarrhythmia and sudden death is expected to be more
frequent in PCCD patients that carry loss-of-function SCN5A
mutations, a disease entity comparable with SCN5A-associated
BrS [180]. Interestingly, overlapping phenotypes of BrS1, LQTS,
and inherited conduction system defects have been reported in
some families [185].
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The diagnosis of PCCD in an index patient is based on clinical data
including history, family history, and 12-lead ECG. The potential
presence of congenital heart disease and/or cardiomyopathy must be
investigated by 2-D echocardiography or other imaging modalities,
such as cardiac MRI. Early-onset PCCD in the absence of structural
heart disease should prompt consideration of PCCD genetic testing,
particularly if there is a positive family history of conduction
abnormalities, pacemaker implants, or sudden death [1].
(Targeted) genetic testing may be considered as part of the
diagnostic evaluation for patients with either isolated PCCD or
PCCD with concomitant structural heart disease, especially when
there is documentation of a positive family history of PCCD [1].
Risk stratiﬁcation
Screening for underlying cardiovascular manifestations with a
resting 12-lead ECG, Holter, or 2-D echocardiogram is recommended,
independent of symptom status. Patients with ﬁrst-degree AV block in
association with bifascicular block and symptomatic advanced AV
block have a substantial incidence of sudden death. In the presence of
permanent or transient third-degree AV block, syncope is associated
with an increased incidence of sudden death regardless of EPS results
[189]. Based on this evidence in patients with PCCD diagnosis, pace-
maker implant may be indicated even in individuals with bifascicular
block and ﬁrst-degree AV block and thus representing an exception to
the recommendation set by international guidelines for patients who
have this phenotype in all the other clinical conditions.
There is no genotype-based risk stratiﬁcation for patients with
PCCD. Some mutations may be associated with development of heart
failure and/or extracardiac features, such as skeletal myopathy, which
can be diagnosed, followed and treated after having PCCD classiﬁed as
a genetic entity [1]. Patients with LMNA mutations may experience
malignant arrhythmias and SCD despite pacemaker implantation
[184]. ICD therapy is therefore warranted at an early stage; a risk
stratiﬁcation scheme has recently been proposed [190].
Management
Once cardiac involvement occurs, particularly with the muscular
dystrophies, the clinician should maintain a low threshold for inves-
tigating symptoms or ECG ﬁndings to determine the need for EPS,
pacemaker or ICD implantation. Screening for underlying cardiovas-
cular manifestations with a resting 12-lead ECG or 2-D echocardio-
gram to determine cardiac involvement should be part of the routine
clinical assessment, independent of symptom status [2]. Asympto-
matic family members who are positive for the family’s PCCD-
associated mutation should be prospectively followed for the early
development of PCCD-related symptoms, deterioration of cardiac
conduction, and beginning signs and symptoms of heart failure. In
addition, medications with conduction-slowing properties should be
restricted, and fever, an aggravating trigger in individuals with SCN5A
mutations, should be preemptively treated [1].
Screening of family members
Cascade family screening is useful in families with mutation-
positive PCCD. When a clinical diagnosis of PCCD is established in an
index case, a careful clinical investigation of ﬁrst-degree family
members is necessary. Genotyping of family relatives is done
after mutation identiﬁcation in the index cases and may be useful to
exclude presence or development of PCCD. Taken together,
a comprehensive clinical and genetic evaluation of family members
is generally recommended to detect inherited forms of PCCD disease
and other cardiac and noncardiac disease features [1].8. Unexplained Cardiac Arrest: Idiopathic VFExpert Consensus Recommendations on Idiopathic Ventricular
Fibrillation Diagnosis
1. IVF is deﬁned as a resuscitated cardiac arrest victim, preferably
with documentation of VF, in whom known cardiac,
respiratory, metabolic and toxicological etiologies have been
excluded through clinical evaluation.Expert Consensus Recommendations on Idiopathic Ventricular
Fibrillation Evaluation
Class IIa
1. Genetic testing in IVF can be usefulwhen there is a suspicion of
a speciﬁc genetic disease following clinical evaluation of the
IVF patient and/or family members.Class III
2. Genetic screening of a large panel of genes in IVF patients in
whom there is no suspicion of an inherited arrhythmogenic
disease after clinical evaluation should not be performed.Expert Consensus Recommendations on Idiopathic Ventricular
Fibrillation Therapeutic Interventions
Class I
1. ICD implantation is recommended in patients with the
diagnosis of IVF.Class IIb
2. Antiarrhythmic therapy with quinidine, PES guided or
empirical,may be considered in patients with a diagnosis of IVF
in conjunction with ICD implantation or when ICD
implantation is contraindicated or refused.
3. Ablation of Purkinje potentials may be considered in patients
with a diagnosis of IVF presenting with uniform morphology
PVCs in conjunction with ICD implantation or when ICD
implantation is contraindicated or refused.
4. If a ﬁrst-degree relative of an IVF victim presents with
unexplained syncope and no identiﬁable phenotype following
thorough investigation, then after careful counseling an ICD
implant may be considered.Expert Consensus Recommendations on Idiopathic Ventricular
Fibrillation Evaluation of Family Members
Class I
1. Evaluation of ﬁrst-degree relatives of all IVF victims with
resting ECG, exercise stress testing and echocardiography is
recommended. Assessment of ﬁrst-degree relatives with
history of palpitations, arrhythmias or syncope should be
prioritized.
2. Follow-up clinical assessment is indicated in young family
members of IVF victims who may manifest symptoms and/or
signs of the disease at an older age and in all family members
whenever additional sudden unexplained death syndrome
(SUDS) or sudden unexplained death in infancy (SUDI) events
occur.Class IIa
3. Evaluation of ﬁrst-degree relatives of IVF victims with Holter
and signal-averaged ECGs, cardiac MRI and provocative testing
with Class Ic antiarrhythmic drugs can be useful.
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4. Evaluation of ﬁrst-degree relatives of IVF victims with
epinephrine infusion may be considered.Deﬁnition
When individuals survive a cardiac arrest we are able to inves-
tigate and treat them for the underlying cause. The term idiopathic
ventricular ﬁbrillation (IVF) is used when the cardiac arrest remains
unexplained despite this investigation. In 1992, when discovery of
the genetic basis of cardiac channelopathies was in its infancy, the
hypothesis was advanced that concealed forms of arrhythmogenic
disorders could underlie these cases representing subclinical “elec-
trical abnormalities” of the heart [191]. A subsequent expert con-
sensus statement [192] deﬁned IVF as “the terminology that best
acknowledges our current inability to identify a causal relationship
between the clinical circumstance and the arrhythmia.” In the same
article, the minimal requirements for the diagnosis of IVF were also
deﬁned [192]. It is therefore expected that the proportion of cardiac
arrests deﬁned as IVF is destined to decrease as we identify more
conditions that may lead to life-threatening arrhythmias in the
absence of overt cardiac abnormalities.
Epidemiology
In the CASPER registry of cardiac arrest survivors, in whom
overt coronary and structural disease had already been excluded,
44% remained without a diagnosis after further comprehensive
evaluation (see below) [193]. There is little other systematic data
on the prevalence of IVF as an entity.Diagnosis
IVF is diagnosed by the exclusion by clinical evaluation of known
cardiac, respiratory, metabolic and toxicological etiologies that may
lead to cardiac arrest. Ideally VF should be documented. The most
recent consensus document deﬁning the minimal requirements for
diagnosis of IVF dates back to 1997. Data from the CASPER registry
[193] suggest that careful clinical assessment of patients surviving a
cardiac arrest in the absence of structural cardiac abnormalities
(normal cardiac function on echocardiogram, no evidence of coronary
artery disease, and a normal ECG) can lead to diagnosis of a disease in
more than half of cases. A staged cascade screening approach was
associated with an incremental diagnostic yield in this cohort: (1) ECG,
signal-averaged ECG, telemetry; (2) imaging (MRI with and without
contrast); (3) provocative tests (exercise stress test, epinephrine
infusion, procainamide); (4) EPS and voltage map; (5) ventricular
biopsy; and (6) targeted genetic testing. A similar yield has been
observed with thorough evaluation of sudden unexplained death
syndrome (SUDS) cases and their relatives [194,195].
Genetic diagnostic testing in IVF cases may be considered when
clinical evaluation is either inconclusive or suggests that a “forme
fruste” of a channelopathy might be present. Several factors may gene-
rate such a suspicion: (1) age, (2) gender, or (3) activity at the time of
cardiac arrest (for example rest, exercise, emotion, or auditory stimuli).
A family history of premature sudden death may also strengthen the
possibility of a genetic substrate. The yield of genetic screening of IVF
patients is heterogeneous. Krahn et al [193] identiﬁed mutations in
47% of patients with suspected IVF by using targeted genetic testing
led by clinical diagnostic testing. However, Bai et al [196] reported that
the yield of genetic screening in IVF patients and family members of
SCD victims is very low in the absence of a clinical suspicion to guidetesting. The cost of screening a large number of genes responsible for
many different diseases is too expensive at this stage to be recom-
mended, particularly as a negative result does not rule them out as
potential the causes of IVF.
Management
In IVF, as there is by deﬁnition no evidence for pathogenesis,
management is empirical and most patients are advised to
undergo an ICD implant. Unfortunately, the natural history of IVF
is poorly deﬁned. Data collected in a small series of patients by
Crijns et al [197] suggested that at 2.8 years of follow-up only 1/10
patients had a recurrence of VT but none experienced ICD shock or
death. Similarly, Belhassen and Viskin [198] reported a multicenter
experience on 26 IVF patients studied with programmed electrical
stimulation (PES) to test VF inducibility (81% of inducible patients).
PES was repeated after administration of quinidine or a combina-
tion of quinidine and amiodarone to test suppression of induci-
bility. At follow-up ranging between 14 and 216 months no VF or
fatalities occurred. Remme et al [199] reported a 43% recurrent
event rate in a long-term follow-up of 37 IVF patients (77 7 41
months). Knecht et al [200] reported their experience in which IVF
patients with recurrent and troublesome VF underwent catheter-
ization and ablation of Purkinje potentials responsible for VPBs
that initiated the arrhythmia. By far the majority (36/38) were free
of VF at 52 months of follow-up. This represents a speciﬁc subset
of IVF patients presenting with frequent ventricular arrhythmias;
most IVF patients do not suffer such a storm after initial resuscita-
tion from cardiac arrest.Screening of family members
Experience of investigating blood relatives of IVF survivors is
limited but supports the possibility of incompletely penetrant disease
being more evident in family members than in the index case, parti-
cularly if only limited investigation is possible due to a poor neurologic
outcome post-arrest [193]. A similar predominantly noninvasive diag-
nostic protocol to that utilized in SUDS families may be employed (see
Section 9). As with families of SUDS victims, it is reasonable that
relatives of IVF survivors who are obligate carriers or have ominous
symptoms such as cardiac syncope should be prioritized for evalua-
tion. In families with IVF, young family members may require periodic
reassessment even if the initial assessment is normal as young patients
may only become cognizant of symptoms at an older age, and certain
diseases have age-related penetrance. Repeated evaluations should
occur if family members become symptomatic or additional suspicious
sudden deaths are identiﬁed in the family. There are no data on appro-
priate interventions for a ﬁrst-degree relative of an IVF victim who
presents with unexplained cardiogenic syncope without an identiﬁ-
able phenotype despite thorough investigation. Consideration should
be given to monitoring with an implantable loop recorder or after
careful counseling the possibility of an ICD implant.9. Unexplained Sudden Cardiac Death: Sudden Unexplained
Death Syndrome (SUDS) and Sudden Unexplained Death in
Infancy (SUDI)Expert Consensus Recommendations on Sudden Unexplained
Death Syndrome Diagnosis
1. It is recommended that an unexplained sudden death
occurring in an individual older than 1 year of age is known as
“sudden unexplained death syndrome” (SUDS).
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Death Syndrome Diagnosis
2. It is recommended that a SUDS death with negative
pathological and toxicological assessment is termed “sudden
arrhythmic death syndrome” (SADS).Expert Consensus Recommendations on Sudden Unexplained
Death Syndrome Evaluation
Class I
1. It is recommended that personal/family history and circumstances
of the sudden death are collected for all SUDS victims.
2. It is recommended that all sudden death victims diagnosed as
SUDS undergo expert cardiac pathology to rule out the
presence of microscopic indicators of structural heart disease.
3. Collection of blood and/or suitable tissue for molecular autopsy/
postmortem genetic testing is recommended in all SUDS victims.Class IIa
4. An arrhythmia syndrome focused molecular autopsy/postmortem genetic testing can be useful for all SUDS victims.Expert Consensus Recommendations on Sudden Unexplained
Death Syndrome Therapeutic Interventions
Class I
1. Genetic screening of the ﬁrst-degree relatives of a SUDS victim
is recommended whenever a pathogenic mutation in a gene
associated with increased risk of sudden death is identiﬁed by
molecular autopsy in the SUDS victim.
2. Evaluation of ﬁrst-degree blood relatives of all SUDS victims
with resting ECG with high right ventricular leads, exercise
stress testing and echocardiography is recommended.
Assessment of obligate carriers and relatives with a history
of palpitations, arrhythmias or syncope should be
prioritized.
3. Follow-up clinical assessment is indicated in young family
members of SUDS victims who may manifest symptoms and/
or signs of the disease at an older age and in all family
members whenever additional SUDS or SUDI events occur.Class IIa
4. Evaluation of ﬁrst-degree relatives of SUDS victims with
ambulatory and signal-averaged ECGs, cardiac MRI and
provocative testing with Class Ic antiarrhythmic drugs can be
useful.Class IIb
5. Evaluation of ﬁrst-degree relatives of SUDS victims withepinephrine infusion may be considered.Expert Consensus Recommendations on Sudden Unexplained
Death in Infancy Diagnosis
1. It is recommended that unexplained sudden death occurring in
an individual younger than 1 year of age with negative
pathological and toxicological assessment is termed “sudden
unexplained death in infancy” (SUDI).Expert Consensus Recommendations on Sudden Unexplained
Death in Infancy EvaluationClass I
1. It is recommended that personal/family history and circumstances
of the sudden death are collected for all SUDI victims.
2. Collection of blood and/or suitable tissue for molecular
autopsy is recommended in all SUDI victims.Class IIa
3. An arrhythmia syndrome focused molecular autopsy/
postmortem genetic testing can be useful for all SUDI victims.Class IIb
4. Sudden death victims diagnosed as SUDI at autopsy may be
considered for assessment by an expert cardiac pathologist to
rule out the presence of microscopic indicators of structural
heart disease.Expert Consensus Recommendations on Sudden Unexplained
Death in Infancy Therapeutic Interventions
Class I
1. Genetic screening of the ﬁrst-degree relatives of a SUDI victim
is recommended whenever a pathogenic mutation in a gene
associated with increased risk of sudden death is identiﬁed by
molecular autopsy in the SUDI victim. Obligate mutations
carriers should be prioritized.Class IIa
2. Evaluation of ﬁrst-degree relatives of SUDI victims with a
family history of inherited heart disease or other SUDS or SUDI
deaths with resting ECG and exercise stress testing and
additional tests as indicated can be useful. Assessment of ﬁrst-
degree relatives with history of arrhythmias or syncope
should be prioritized.
3. Follow-up clinical assessment can be useful in young family
members of SUDI victims with a family history of inherited heart
disease or other SUDS or SUDI death who may manifest
symptoms and/or signs of the disease at an older age and in all
family members whenever additional SUDS or SUDI events occur.Class IIb
4. Evaluation of ﬁrst-degree relatives of SUDI victims with
resting ECG and exercise stress testing may be considered.Deﬁnitions
SCD is a common outcome of “acquired” cardiac diseases such
as acute myocardial ischemia and ischemic dilated cardiomyopa-
thy where the cause is readily determined [201]. An unexplained
SCD, however, is a pathological diagnosis of exclusion that covers a
number of possible etiologies. A commonly used term is “sudden
arrhythmic death syndrome” (SADS), which describes a SCD where
an autopsy and toxicology have been undertaken, noncardiac
etiologies excluded and the heart found to be morphologically
normal [202,203]. Another similar descriptor, “sudden adult death
syndrome,” [204] has been termed to describe nonpediatric cases.
In Southeast Asia, cases of young male sudden deaths have been
attributed to “sudden unexpected or unexplained death syndrome”
(SUDS) as well as “sudden unexpected nocturnal death syndrome”
(SUNDS). These have, however, been directly related to BrS as an
etiology, have been used interchangeably and do not necessarily
imply a through pathological evaluation [205]. The terms “sudden
infant death syndrome” (SIDS) or “sudden unexpected death in
infancy” (SUDI) are used in cases under 1 year of age when the
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stringent circumstantial and forensic investigation. These are
discussed further below [206].
The deﬁnitions utilized for unexplained SCD have varied. The
timing of unwitnessed deaths (less than 1 hour to less than 24
hours) is one factor [202,203,207,208]. Another is the limited or
even absence of access to autopsy in some countries and a
histopathological examination may be the exception rather than
the rule [207,209,210]. If an autopsy has not been undertaken or
considered inadequate then the death remains unexplained, but
other etiologies, genetic and acquired, should be considered and a
broader diagnostic view needs to be considered. Consistent use of
the descriptors SUDS and SADS would be similar to the use of SUDI
and SIDS and will help reduce confusion over terminology. This
will ensure that familial evaluation is guided toward the diagnosis
of likely etiologies such as arrhythmia syndromes.
Epidemiology
It is clear that the relevant International Classiﬁcation of Diseases
codes (ICD codes) for unexplained SCD underestimate signiﬁcantly its
true frequency [203]. The incidence and prevalence of unexplained
SCD depend, however, upon the population studied and the investi-
gators. Autopsies for unexplained sudden death are mandatory in the
United Kingdom. The incidence of unexplained SCD among the
general population aged 4 to 64 years has been estimated to be up
to 1.34/100,000 per annum [203], with 4.1% of SCD in the 16- to 64-
year age group being unexplained [204]. A recent Irish study reported
an incidence of unexplained SCD of 0.76/100,000 year in subjects
aged 14 to 35 years old accounting for 27% of the total incidence of
SCD [211]. Danish data are limited by a 75% autopsy rate but supports
an incidence of at least 0.8/100,000 per annum among 1 to 35 year
olds with 43% of autopsied cases being unexplained [207]. Not only is
the proportion of SCD that remains unexplained apparently higher in
the young but victims are more commonly young men who die
suddenly in their sleep or at rest [203]. Among predominantly male
U.S. military recruits aged 18 to 35 years old the unexplained SCD
rates is as high as 4.5/100,000 per annum, accounting for 35% of all
SCD in this group [212]. A regional Australian study of SCD in the 5 to
35 year old group conﬁrms a 29% proportion as unexplained [213].
An autopsy series of the general population in the Veneto region of
Italy has, however, suggested that normal hearts are present in only
6% of SCD cases [208], while a U.S. series of sudden deaths among
athletes found only a 3% prevalence [214]. Conversely, sudden deaths
among British athletes contained a 26% prevalence of morphologi-
cally normal hearts [215]. There is therefore remarkable variation and
discrepancy.
The incidence of unexplained sudden death below 1 year of age
(SIDS and SUDI) is well deﬁned and exceeds the incidence of SCD in
young adults or in children over 1 year of age by an order of
magnitude. A recent national study from Ireland revealed a sudden
death rate of 1.4/100,000 among children age 1–4 years compared to
59/100,000 in those under 1 year [216]. A population based-study in
the United States revealed similar rates with an annual incidence of
SCD of 3/100,000 for children age 1–4 years and 80/100,000 for
children o1 year [217]. It should be noted that campaigns to avoid
modiﬁable risk factors (predominantly avoiding the prone sleeping
position) have resulted in signiﬁcant declines in SIDS rates around the
world. However, these have plateaued and the current rate of SIDS in
the United States is 53/100,000 [218].
Diagnosis
The diagnosis of an unexplained SCD ideally relies upon an
autopsy and toxicological studies being undertaken to exclude
noncardiac etiologies. Further pathological evaluation of the heart isthen necessary with detailed histopathological examination to exclude
clear causes for SCD [219]. This may identify structural cardiac genetic
disease such as hypertrophic cardiomyopathy that would indicate the
need for familial evaluation and the retention of tissue suitable for
DNA extraction and targeted genetic testing. This examination is best
undertaken with the support of an expert cardiac pathologist to
improve the accuracy of diagnosis and guide familial evaluation
[210]. In a number of cases pathological ﬁndings may be equivocal
as to the cause of death: for example, idiopathic left ventricular
hypertrophy without histological disarray; bicuspid aortic valve; or
anomalous coronary artery without evidence for ischemia. These
should be considered unexplained as familial evaluation can still
uncover a signiﬁcant burden of arrhythmia syndromes in these cases
[220]. If the death remains unexplained, then additional investigations
may prove helpful. Collection of any available antemortem history or
cardiac investigation may provide clues but a normal antemortem ECG
does not exclude an underlying cardiac genetic cause, particularly
when BrS has been diagnosed in the family [221]. Retention of tissue
suitable for DNA extraction permits a molecular autopsy to either
conﬁrm a genetic diagnosis or evenmake the diagnosis in up to 35% of
cases [222]. This may also prove helpful in the event of a SUDI death as
postmortem genetic testing reveals mutations in cardiac channelo-
pathy genes in an estimated 10% of SIDS cases [222].
Management
Once a diagnosis of SUDS has been made, further management
revolves around evaluating family members.
Screening of family members
When ﬁrst-degree relatives of victims of SADS or premature
(less than 50 years old) unexplained sudden death undergo
cardiac assessment, up to half of families reveal cardiac genetic
diseases such as the arrhythmia syndromes (LQTS, BrS and CPVT in
particular) and occasionally subtle and difﬁcult to detect forms of
cardiomyopathy (ARVC in particular) [202,209,223,224]. If an
autopsy has not been undertaken then additional etiologies
diagnosed in families include cardiomyopathies in general and
familial hypercholesterolemia [209,223]. The strategy for evalua-
tion often is staged with less invasive investigations ﬁrst and then
more invasive tests if a diagnosis is not made (Fig. 3). Family
members who are more likely to be affected include those with
symptoms of concern such as syncope or seizure, and obligate
carriers [224]. The investigative protocol may include personal
history; family history and history of sudden death victim; resting,
exercise, signal-averaged and ambulatory 24 hour ECG; echocar-
diography; and provocation testing with sodium channel blocker
and/or epinephrine and cardiac MRI as required [202,209,223,
224]. Signal-averaged and ambulatory ECGs are least effective in
making a clinical diagnosis [209,224]. Resting and exercise ECG,
Class I drug challenge and cardiac imaging offer the most diag-
nostic value consistently across studies [209,224]. A retrospective
revision of an autopsy diagnosis by an expert pathologist may also
support a diagnosis in a family [209].
The investigation of family members of cases of SUDI deaths
often occurs on an ad hoc basis yet there are little data on its yield.
Molecular autopsy identiﬁes a lower burden of ion channel disease
in SIDS compared to SUDS and there is a greater likelihood of
sporadic genetic disease as a cause of sudden death in infancy. It is
therefore likely that the yield of clinical evaluation of ﬁrst-degree
relatives will be signiﬁcantly lower than in SUDS. Nonetheless if
there is a positive molecular autopsy result, a family history of
other cases of SUDI, SUDS or premature unexplained sudden death
or of inherited heart disease then the yield is likely to be greater
and familial evaluation more worthwhile.
Fig 3. Algorithm to describe the investigative strategy for identiﬁcation of inherited heart disease in families that have suffered a SUDS event.
S.G. Priori et al. / Journal of Arrhythmia 30 (2014) 1–28 19As with families of SUDS victims, it is reasonable that relatives of
SUDI deaths who are obligate carriers or have ominous symptoms
such as cardiac syncope should be prioritized for evaluation. In
families with SUDS deaths young family members may require
periodic reassessment even if the initial assessment is normal as
young patients may only become cognizant of symptoms at an older
age, and certain diseases have age-related penetrance. Repeated
evaluations should occur if family members become symptomatic
or additional suspicious sudden deaths are identiﬁed in the family.
10. Inherited Arrhythmia ClinicsExpert Consensus Recommendation on Inherited Arrhythmia
Clinic
Class I
Patients (probands) and ﬁrst-degree relatives with a diagnosed
or suspected inherited cardiovascular disease as a potentialcause of SCD (SUDS/SUDI) should be evaluated in a dedicated
clinic with appropriately trained staff.
The evaluation and treatment of families suspected of having
inherited arrhythmias requires a multidisciplinary team and approach.
The presentation often is that of a proband or family member who has
experienced a life-threatening arrhythmia, sudden cardiac arrest or
SCD. In the usual circumstance, there are profound and far-reaching
medical and psychosocial implications of both presentation of the
inherited arrhythmia and genetic testing on patients and families [1,2]
The presence of an inherited arrhythmia or a positive genetic test can
dramatically change the life of a patient and questions related to
transmissibility of disease to one’s children, participation in athletics,
insurability and prohibited types of employment are among the
common questions patients and families face. Perhaps the most
important role of the inherited arrhythmia clinic in the case of the
sudden death of a proband is to provide support, expert evaluation,
advice and treatment to surviving family members.
S.G. Priori et al. / Journal of Arrhythmia 30 (2014) 1–2820Recent evidence suggests that a structured inherited arrhyth-
mia (or inherited cardiovascular disease) clinic improves the
likelihood of making a diagnosis in suspected cases of inherited
arrhythmias and SCD [196,209,224–227]. The promise of an
appropriately resourced, structured clinic is that of a comprehen-
sive evaluation of patients and families, more efﬁcient use of
diagnostic testing and therapy and ready access to a broad range of
medical, genetics and psychosocial expertise in managing families
afﬂicted by inherited arrhythmias. An inherited cardiovascular
disease clinic is an invaluable resource to patients and families,
not only at the time of the initial evaluation but in an ongoing
fashion as medical, genetic and social questions relevant to the
inherited heart disease arise.
There are different operational models for inherited arrhythmia
clinics; the choice may be determined by the health system or the
regulations that exist in a given country. However, the linchpins of
a successful inherited heart disease clinic include not only medical,
nursing and genetics proﬁciency but a dedicated staff with opera-
tional and logistic expertise who have ready access to all team
members. Each member of the team has a key role to play in the
optimal evaluation of families suspected of having inherited
arrhythmias. The personnel and workﬂow in an ideal inherited
arrhythmia clinic are illustrated in the schematic in Fig. 4. The key
personnel include a clinic coordinator who is responsible for
patient intake, collection and collation of medical records, sche-
duling appointments for patients and family members and assist-
ing with questions relating to insurance coverage. The initial
evaluation of patients and family members may be performed by
a nurse specialist and genetics counselor [228]. This requires not
only review of medical records but also pedigree development,
collection and collation of medical testing such as imaging studies,
pathological specimens, autopsy reports and results of previously
performed genetic testing. In the ideal situation, the results of
testing on the patient or family members are reviewed by theFig. 4. Workﬂow and personnel in the evaluation of pphysicians, nurses and counselors prior to the clinic visit. The
physicians are typically a clinical cardiologist/electrophysiologist
with expertise in inherited arrhythmias and medical genetics or a
medical geneticist with an interest in cardiac arrhythmias partner-
ing with a clinical electrophysiologist. In some countries, only a
geneticist is permitted to order and/or discuss genetic test results
with patients. It is important to bear in mind that many presenta-
tions that suggest an inherited arrhythmia may be the result of
acquired disease or an inherited cardiomyopathy. If the inherited
arrhythmia clinic is part of a larger program in inherited heart
disease, experts in cardiomyopathy will likely be available; other-
wise access to such experts is essential. The team of physicians will
perform the general medical evaluation of the patient, review of
the records, interpretation of test results and development of
diagnostic and identify the treatment plans. In some cases evalua-
tion of a family includes postmortem review of a family member
and the opinion of a cardiac pathologist often is useful in making
the proper diagnosis.
The increasing complexity and demands of the proper diag-
nosis and management of patients with inherited cardiovascular
disease create an opportunity for the development of specialized
training for clinical electrophysiologists interested in the care of
patients with inherited arrhythmias [229]. Such a specialty track
would consolidate aspects of care involving indications and inter-
pretation of genetic test results and pharmacological and device
therapy.
The management of patients with inherited arrhythmias
includes expert judgment regarding the indications, type and
interpretation of genetic testing. In collaboration with a genetic
counselor, patients and families should be properly prepared
regarding expectations and outcomes of genetic testing. The role
of genetic testing may vary depending upon the exact inherited
arrhythmia being considered, and the particular mutation may
have an impact on speciﬁc therapeutic recommendations.atients and families with inherited arrhythmias.
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S.G. Priori et al. / Journal of Arrhythmia 30 (2014) 1–2824Arguably the most important part of the testing procedure is
reviewing the test results and implications with patient and
family, being prepared to discuss the implications for other family
members, the meaning of variants of uncertain signiﬁcance (VUS),
mosaicism and issues related to paternity and consanguinity. The
genetic counselor is an essential [228] and in some countries
legally mandated provider in this aspect of the care of patients and
families with suspected inherited arrhythmias.
The genetic test is only part of the management of a patient
with an inherited arrhythmia. The treatment of patients with
inherited arrhythmias may vary from medication therapy and
lifestyle modiﬁcation to device implantation to LCSD. Patients
may require invasive EPS and treatment with pacemakers or ICDs.
In some cases surgical or thoracoscopic cardiac sympathetic
denervation is required for cardiac rhythm control and SCD
prevention. In general patients will require adjustment to both
the underlying disease and therapy, which could be assisted by
access to psychologists with an interest in patients with heart
disease.
Patients in an inherited arrhythmia clinic may be survivors of
SCA. The management of the recovery of these patients from their
index event may require the expertise of psychologists and
psychiatrists and the intervention of physical and occupational
therapists. Moreover, the diagnosis of an inherited disease of any
kind, particularly one that carries with it the risk of signiﬁcant
morbidity and premature mortality, is often associated with
signiﬁcant emotional distress that at times will require referral
of patients and families [230–236].
A structured inherited arrhythmia (or heart disease) clinic
provides the platform for optimized, multidisciplinary evaluation
and management of patients and families with suspected inher-
ited heart disease. The collective efforts of the core staff and access
to a variety of experts in related disciplines will result in improved
quality of care [224,226,233,237–242], patient satisfaction [233],
and improvement in appropriate use of diagnostic testing
[196,209] and therapeutic intervention. The promise of such a
clinic structure is lower overall cost and improvement in patient
outcomes.Appendix A
See Tables A1 and A2.References
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